CGTDACH2026 | Big Pharma

CGTDACH2026 | Big Pharma

By IMAPAC Pte Ltd

Advancing Scalable, Compliant & Innovative CGT Production in the DACH Region

Date and time

Location

Switzerland

Switzerland Switzerland Switzerland Switzerland

Agenda

Unlocking Commercial Success in DACH's CGT

What's Next for Bioprocessing in CGT?

Overcoming Bottlenecks in Viral Vector Manufacturing

Decentralised Production for NextGen CGTs

Quality Assurance in CGT

Novel Purification & Intensification Strategies

Manufacturing Innovations for Allogenic & In Vivo Therapies

Smart Factories: The Role of Digitalisation & AI

Good to know

Highlights

  • 1 day 10 hours
  • In person

Refund Policy

No refunds

Highlights

  • 1 day 10 hours
  • In person

Refund Policy

No refunds

About this event

Science & Tech • Science

As the Cell & Gene Therapy (CGT) industry matures, the DACH region is emerging as a critical hub for commercial manufacturing and global supply. Yet, the road from clinical promise to large-scale delivery remains paved with technical, regulatory, and supply chain challenges — particularly in viral vector capacity, closed-system adoption, and digital factory readiness.


CGT Manufacturing DACH 2026 will unite leaders from biopharma, biotech, CDMOs, regulators, and technology innovators to exchange practical solutions for scaling production, maintaining quality, and enabling global distribution.

Organised by

IMAPAC Pte Ltd

Followers

--

Events

--

Hosting

--

£3,273.60
Feb 11 · 08:00 GMT+1